Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Halozyme Therapeutics Q4 Adj EPS $0.82 Misses $0.83 Estimate, Sales $230.04M Miss $233.19M Estimate

Author: Benzinga Newsdesk | February 20, 2024 05:03pm
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.82 per share which missed the analyst consensus estimate of $0.83 by 1.2 percent. This is a 70.83 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $230.04 million which missed the analyst consensus estimate of $233.19 million by 1.35 percent. This is a 26.75 percent increase over sales of $181.50 million the same period last year.

Posted In: HALO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist